• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Endure Biotherapeutics, Inc.

Thursday, June 06, 2024
Start-Up Stadium Session
Platform for Therapeutics
Company Description: Endure Biotherapeutics (“Endure Bio”®) is developing engineered engraftable live biotherapeutics for metabolic diseases by genetically engineering human native bacteria to express therapeutic compounds. Endure’s advantage is its Engineered Native Bacteria (ENB) platform technology. Unlike other microbiome therapeutics, ENB-based biotherapeutics overcome the traditional challenges of first-generation products, allowing for engraftable knock-in function with infrequent administration, delivering potentially curative solutions that remain resident and endure the host environment. The company has an initial focus on orphan disease applications, specifically targeting phenylketonuria (PKU), a >$2.4 billion market with significant unmet need. Our broadly applicable platform has the potential to span therapeutic areas including metabolism, oncology, and IBD, leading to significant opportunities for partnerships with other companies to develop and commercialize.

Endure Biotherapeutics, Inc.
Company Website: https://endurebio.com/

Company HQ City

Carlsbad

Company HQ State

Ca

Company HQ Country

United States

CEO/Top Company Official

Mark S. Wilson
Primary Speaker
Mark Wilson, MBA
CEO
Endure Biotherapeutics, Inc.
Back to Session List

white squarewhite

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS